Patents Examined by Amy L. Clark
  • Patent number: 12213963
    Abstract: The present invention relates to a composition of disease-modifying antirheumatic drugs (DMARDs) for treatment of auto-immune diseases. More particularly, the invention relates to the microemulsion based emulgel composition of DMARD-leflunomide or its derivatives for treatment of auto-immune diseases such as rheumatoid arthritis, atopic dermatitis, psoriasis and skin cancer such as melanoma, squamous cell carcinoma. The invention also discloses a method for preparation of microemulsion based emulgel composition with improved physicochemical, pharmacokinetic properties of leflunomide to be used in pharmaceutical compositions. This invention discloses the delivery of leflunomide across human skin for the treatment of autoimmune and oncological conditions. The unique delivery of leflunomide in the form of microemulsion based emulgel composition is disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: February 4, 2025
    Inventor: Manoj Purushottam Jadhav
  • Patent number: 12194029
    Abstract: Methods of treating cancer in a patient by administering ethyl-1-(substituted benzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates to a patient in need thereof.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: January 14, 2025
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Vijaykumar Uppar, Rashmi Venugopala, Sandeep Chandrashekharappa, Basavraj Padmashali, Viresh Mohanlall
  • Patent number: 12186287
    Abstract: Disclosed is a patch comprising an adhesive layer on a backing layer, wherein the adhesive layer comprises lidocaine or a pharmaceutically acceptable salt thereof, propylene glycol, a rubber adhesive base and a terpene resin, wherein the content of the lidocaine or a pharmaceutically acceptable salt thereof in the adhesive layer in terms of free form is 2 mass % to 6 mass % with respect to the total mass of the adhesive layer, wherein the ratio of the mass of the lidocaine or a pharmaceutically acceptable salt thereof in terms of free form to the mass of propylene glycol in the adhesive layer is 1:0.6 to 1:1.8, and wherein the content of the terpene resin in the adhesive layer is 5 mass % to 18 mass % with respect to a total mass of the adhesive layer.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: January 7, 2025
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Kentaro Nakashima, Yusuke Tanaka, Keiichiro Tsurushima
  • Patent number: 12180166
    Abstract: An 6-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)hexanoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: February 8, 2024
    Date of Patent: December 31, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 12133851
    Abstract: Disclosed herein are methods of treating cholangiocarcinoma in a patient comprising: evaluating a biological sample from the patient for the presence of one or more FGFR mutants including at least the mutation FGFR3 R397C; or one or more FGFR mutants including at least the mutation FGFR3 L608F; or one or more FGFR mutants including at least the fusion FGFR2-TACC2; and treating the patient with an FGFR inhibitor if one or more FGFR mutants including at least the mutation FGFR3 R397C; or one or more FGFR mutants including at least the mutation FGFR3 L608F; or one or more FGFR mutants including at least the fusion FGFR2-TACC2 are present in the sample.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: November 5, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventor: Jacqueline Cirillo Bussolari
  • Patent number: 12023338
    Abstract: A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: July 2, 2024
    Assignee: KYOTO UNIVERSITY
    Inventors: Masatoshi Hagiwara, Masahiko Ajiro
  • Patent number: 11766423
    Abstract: Methods for treating one or more diseases associated with neutral sphingomyelinase 2 (nSMase2) in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of 2,6-dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) or a pharmaceutically acceptable salt thereof, are disclosed.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: September 26, 2023
    Inventors: Barbara Slusher, Camilo Rojas, Ajit G. Thomas, Norman Haughey, Marc Ferrer, Xin Hu
  • Patent number: 11752182
    Abstract: The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and mixtures of species, to provide an armamentarium of defenses from multiple stressors in order to help bees survive a complex of symptoms collectively called colony collapse disorder (CCD). More particularly, the present invention utilizes specific concentrations of extracts from pure cultured mycelium from mushroom forming fungi to reduce harmful viruses in bees and to increase the longevity of bees.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: September 12, 2023
    Assignee: TURTLE BEAR HOLDINGS, LLC
    Inventor: Paul Edward Stamets
  • Patent number: 11723942
    Abstract: Disclosed are powder solid compositions including a hydroalcoholic extract of Bergamot fruit (Citrus aurantium var. bergamia) and at least one phospholipid. Also disclosed is a process for the preparation of the compositions. The compositions are useful for the prevention and/or treatment of dysmetabolic syndromes, dyslipidemias and type 2 diabetes.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: August 15, 2023
    Assignee: INDENA S.P.A.
    Inventors: Massimo Ronchi, Giacomo Mombelli
  • Patent number: 11717552
    Abstract: An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: August 8, 2023
    Assignee: ALPHANOSOS S.A.S.
    Inventors: Pascal Mayer, Laure Breuils
  • Patent number: 11654120
    Abstract: This disclosure relates to new compositions and methods for treating skin conditions as a result of sun damage. In one embodiment this disclosure pertains to new compositions for treating or preventing sunburns, skin damage, and/or harm from radiation, such as UV radiation.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: May 23, 2023
    Assignee: OLLIE'S HEALTH, LLC
    Inventor: Marshall Ollie Almarode
  • Patent number: 11648233
    Abstract: The present invention is related to an active substance of Hericium erinaceus having a pain-relieving effect, and a pharmaceutical composition including the active substance. The active substance is prepared using the following steps: (a) inoculating a mycelium of H. erinaceus on an agar plate and incubating at 15-32° C. for 8-16 days; (b) inoculating the incubated H. erinaceus mycelia from step (a) into a medium in a flask and incubating at 20-30° C. and pH 4.5-6.5 for 3-5 days; (c) inoculating the incubated H. erinaceus mycelia from step (b) into a medium in a fermentation tank and incubating at 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the H. erinaceus mycelia; and (d) desiccating the fermented medium of the H. erinaceus mycelia from step (c) to obtain the powder of the H. erinaceus mycelia, which is further purified and isolated to obtain a novel compound of H. erinaceus.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 16, 2023
    Assignee: GRAPE KING BIO LTD.
    Inventors: Pei-Shan Liu, Chien-Chih Chen, Chin-Chu Chen, Li-Ya Lee, Wan-Ping Chen, Ting-Wei Lin, Jui-Hsia Hsu, Wei-Ching Chu
  • Patent number: 11617774
    Abstract: The present invention relates to a composition for preventing and/or treating a stroke or a degenerative brain disease comprising: at least two substances selected from the group consisting of egg yolk lecithin, glycerol, sodium oleate, medium chain triglyceride and refined fish oil; olive oil; and soybean oil. The composition of the present invention has an excellent neuroprotective effect but no toxicity or side effects, and thus can be effectively and safely used for preventing, treating or ameliorating a stroke or a degenerative brain disease.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 4, 2023
    Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
    Inventors: Jin Gyu Choi, Donghun Lee, Juyeon Park, Jungbin Song, Hocheol Kim
  • Patent number: 11590193
    Abstract: A plant extract obtained from saffron, with a safranal concentration, measured using the HPLC method, of a minimum of 0.2% by weight relative to the total dry matter weight. A method for obtaining the plant extract, as well as compositions comprising the plant extract, and methods of treatment.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: February 28, 2023
    Assignee: ACTIV'INSIDE
    Inventors: David Gaudout, Stephane Rey, Benoit Lemaire, Benjamin Moras, Marion Dumoulin
  • Patent number: 11564943
    Abstract: The invention refers to a decomposed platelet concentrate containing ?50% intact platelets and optionally ?200 pg/ml RANTES and specifically to its use in the prevention or treatment of hair loss and/or for promoting hair growth. The invention further refers to a composition comprising the decomposed platelet concentrate and body fat cells and the use of said composition for reconstructive and aesthetic and curative surgery and pain relief treatment.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 31, 2023
    Inventor: Edvin Turkof
  • Patent number: 11547731
    Abstract: Methods of treating inflammation, pain or both inflammation and pain in a subject are provided. The method includes the step of administering a human birth tissue material composition on or within an affected site of a body. The methods are particularly suitable for treatment of inflammation, pain or both inflammation and pain arising from a viral infection.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: January 10, 2023
    Assignee: BRAHM HOLDINGS, LLC
    Inventor: Timothy R. Brahm
  • Patent number: 11504315
    Abstract: The present invention relates to cosmetic formulations with a high moisturizing power comprising, as active principle, ucuuba (Virola surinamensis) butter comprising myristic acid in high concentration, more particularly in a concentration equal to or greater than 70% of the constitution of said butter. Additionally, the invention relates to products comprising such cosmetic formulations, as well as to the use of ucuuba butter for the preparation of a differentiated cosmetic product with high skin moisturizing power, as will be demonstrated in the present patent application. The invention further discloses a cosmetic kit comprising the formulation disclosed with a suitable applicator and instructions for use.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 22, 2022
    Assignee: Natura Cosméticos S.A.
    Inventors: Aurora Maria Domingues Furtado Grafin Von Ysenburg-Philippseich, Simone Emidio, Daniela Veloso Okuta, Debora Cristina Castellani, Mariane Spadoto, Roberta Gisele de Souza Oliveira Pereira, Roberta Roesler, Wagner Franzin Rusca
  • Patent number: 11497785
    Abstract: The present invention relates to a composition for use as an oral anti-parasitic, the composition comprises one or more of an essential oil which contains gamma-terpinene, and/or carvacrol, and/or thymol, and/or terpinenol, and/or eucalyptol and/or eugenol, an essential oil of genus Cinnamomum, Eugenia, Eucalyptus or a source of saponin. It also relates to a method of preventing or treating parasitic infection in an animal, the method comprising orally administering to said animal a composition comprising one or more of an essential oil which contains gamma-terpinene, and/or carvacrol, and/or thymol, and/or terpinenol, and/or eucalyptol and/or eugenol, an essential oil of genus Cinnamomum, Eugenia, Eucalyptus or a source of saponin.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 15, 2022
    Assignee: MARS, INCORPORATED
    Inventors: Alexandre Feugier, Nicolas Lerouxel
  • Patent number: 11433020
    Abstract: Formulations such as serums to treat skin discoloration via a multi-modal approach are provided in some embodiments. In several embodiments, the formulations are configured to allow select ingredients to work together to effectively brighten skin and treat hyperpigmentation. In several embodiments, the formulations comprise a first anti-melanin agent, such as a Bidens pilosa extract, a second anti-melanin agent, such as a Rheum rhaponticum extract, and an anti-inflammatory agent, such as a Vitamin E compound. In several embodiments, the formulation is provided as a topical formulation.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: September 6, 2022
    Assignee: COLORESCIENCE, INC.
    Inventors: Patricia McGill Boland, Deborah Eileen Gregg Bouche, John Anthony Garruto, Bethany Ann McCarver
  • Patent number: 11426438
    Abstract: Synergistic nutraceutical or pharmaceutical anti-inflammatory compositions include a therapeutically effective combination of: an extract selectively enriched in 3-O-acetyl-11-keto-?-boswellic acid (AKBA) derived from Boswellia serrata; and a Boswellia serrata non-acidic resin extract (BNRE). The compositions can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, and/or endothelial dysfunction. The invention further discloses the amelioration of pro-inflammatory biomarker proteins or molecules, whose expression/production is altered during inflammatory diseases.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 30, 2022
    Assignee: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti, Kiran Bhupathiraju, Venkata Krishna Raju Alluri